Eliot Forster, an industry veteran, has become chief executive of F-star Biotechnology Ltd, a developer of bispecific antibodies that target the immune system to fight cancer. He succeeds John Haurum, the previous CEO.
Dr Forster has been a pharma industry executive for more than 25 years, most recently as CEO of Immunocore Ltd, which is developing bispecific biologics for cancer and infectious and autoimmune diseases. Prior to this, he held senior positions at Pfizer Inc and GlaxoSmithKline Plc.
F-star announced the appointment on 15 October 2018.
Copyright 2018 Evernow Publishing Ltd